Prevention of experimental endotoxin shock by a monocyte activator.

Antimicrobial Agents and Chemotherapy
B PasslickH W Ziegler-Heitbrock

Abstract

In patients with polytrauma or major surgery, severe bacterial infections leading to septic shock and multiorgan failure are still a major cause of death. Prevention of septic shock in patients at risk would be an alternative to treatment of patients with overt septic shock. We therefore conducted a trial with the monocyte activator muramyl tripeptide phosphatidylethanolamine (MTP-PE) in an experimental pig model. Liposome encapsulated MTP-PE (50 micrograms/kg of body weight) or liposomes alone were given intravenously at 72 or 24 h before endotoxemia was induced by lipopolysaccharide (LPS), simultaneously with the induction of endotoxin shock, or 1 h thereafter. Pretreatment with MTP-PE at 72 and 24 h before endotoxemia was induced resulted in a reduction of endotoxin shock-induced mortality from 81.8% (9 of 11 animals) in the control group to 8.3% (1 of 12 animals) of the MTP-PE-pretreated animals (P < 0.001). The administration of MTP-PE 24 h before the induction of endotoxin shock was more effective (P < 0.01) than administration of MTP-PE 72 h before endotoxemia was induced (P = 0.05). The pretreated animals did not develop fever or cardiovascular complications, and pulmonary function was significantly improved. Furthermor...Continue Reading

References

May 1, 1977·Proceedings of the National Academy of Sciences of the United States of America·L ChedidE Lederer
Dec 1, 1992·The Journal of Experimental Medicine·E A FreyS D Wright
Aug 1, 1992·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·E S KleinermanN Jaffe
Oct 1, 1990·AIDS Research and Human Retroviruses·J K LazdinsE Alteri
Aug 1, 1991·Clinical and Experimental Immunology·C KrügerW Schönfeld
Jul 1, 1991·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·A FaradjiJ P Bergerat
Dec 1, 1990·Proceedings of the National Academy of Sciences of the United States of America·J G HaasH W Ziegler-Heitbrock
Dec 1, 1989·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·J L MurrayJ U Gutterman
Jun 21, 1989·Journal of the National Cancer Institute·E G MacEwenP E Howard
Oct 24, 1986·Science·K J TraceyJ D Albert
Nov 1, 1994·Scandinavian Journal of Immunology·H W Ziegler-HeitbrockM O Labeta
Mar 1, 1995·The Journal of Experimental Medicine·C FearnsD J Loskutoff
Jun 30, 1947·The Journal of Experimental Medicine·P B Beeson, UNKNOWN Technical Assistance of Elizabeth Roberts

❮ Previous
Next ❯

Related Concepts

Related Feeds

CRISPR Screens in Drug Resistance

CRISPR-Cas system enables the editing of genes to create or correct mutations. This feed focuses on the application of CRISPR-Cas system in high-throughput genome-wide screens to identify genes that may confer drug resistance.